Gapping down
News:
- BTAI -6% (announces $25 million registered direct offering)
- NUVB -3.5% (Nuvation Bio and AnHeart Therapeutics Ltd. have entered into a definitive agreement for Nuvation Bio to acquire AnHeart in an all-stock transaction)
- BYSI -2.2% (Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer)
- APLT -1.8% (files for 14,285,714 shares of common stock by selling shareholders)
- UUUU -1.8% (files mixed securities shelf offering)
- CC -1.4% (names Denise Dignam as CEO, she had been interim CEO; Matthew Abbott will remain as Interim CFO as co searches for permanent CFO)
- REGN -1.3% (FDA has issued Complete Response Letters for the Biologics License Application for odronextamab in relapsed/refractory follicular lymphoma and in R/R diffuse large B-cell lymphoma, each after two or more lines of systemic therapy)
Analyst comments:
- BIGC -5.5% (downgraded to Underperform from Neutral at BofA Securities)
- SMG -1.8% (downgraded to Mkt Perform from Strong Buy at Raymond James)
- PLAY -1.6% (downgraded to Mkt Perform from Outperform at Raymond James)
- RIVN -1.6% (downgraded to Neutral from Buy at Mizuho)
- TSLA -1.2% (downgraded to Neutral from Buy at Mizuho)